Vitamin B12 and Chemotherapy: Neuropathy and Supplementation

Vitamin B12 sits at a complicated crossroads in cancer treatment. The vitamin is essential for DNA synthesis and nerve health, but many chemotherapy drugs work by disrupting the very metabolic pathways B12 supports. That creates a tangled relationship: some chemo regimens require B12 supplementation to keep toxicity manageable, while emerging research raises questions about whether supplementing B12 during other regimens could interfere with treatment. For cancer patients, the answer to “should I take B12?” depends heavily on which drugs they are receiving, what surgery they have had, and whether they are already deficient.

Why B12 Matters in the Context of Chemotherapy

B12 is a key player in what biochemists call one-carbon metabolism, a network of reactions that cells rely on to make DNA building blocks, regulate gene expression, and maintain the protective coating around nerves. Folate (vitamin B9) works alongside B12 in these pathways.¹ Several widely used chemotherapy drugs, including methotrexate and pemetrexed, are designed to block parts of this same machinery. They stop cancer cells from copying their DNA, but they also affect healthy cells that divide rapidly, like those lining the gut and bone marrow. When B12 levels are low, healthy cells become even more vulnerable to that collateral damage, which is why the vitamin’s status before and during treatment matters so much.

Pemetrexed and Mandatory B12 Supplementation

Pemetrexed, a drug commonly used in non-squamous non-small cell lung cancer and mesothelioma, is the clearest case where B12 supplementation is not optional. The drug targets the folate pathway so aggressively that, without supplemental B12 and folic acid, patients face substantially higher rates of dangerous drops in blood cell counts, severe mouth sores, and other toxicities. Standard practice calls for a B12 injection (typically 1,000 micrograms intramuscularly) before the first cycle and every three cycles thereafter, along with daily oral folic acid.

Clinical guidelines originally recommended starting B12 and folic acid at least seven days before the first pemetrexed infusion.² In practice, though, that lead-in time can delay treatment, which is stressful for patients eager to start. A randomized trial (the PEMVITASTART trial) found that starting B12 and folic acid on the same day as the first pemetrexed-platinum infusion did not increase blood-related toxicity compared to the traditional week-long lead-in.³ That finding has made many oncologists more flexible about timing, though the supplementation itself remains non-negotiable.

The Peripheral Neuropathy Connection

Chemotherapy-induced peripheral neuropathy, the tingling, numbness, and sometimes burning pain in the hands and feet, is one of the most dreaded side effects of treatment. Drugs like taxanes (paclitaxel, docetaxel), platinum agents (cisplatin, oxaliplatin), and vinca alkaloids are the usual culprits. B12 deficiency causes its own form of nerve damage through a completely different mechanism, by disrupting the maintenance of the myelin sheath that insulates nerve fibers. When both problems stack, the neuropathy can be more severe and harder to reverse.

Research has identified functional B12 deficiency, measured by elevated levels of a metabolite called methylmalonic acid (MMA), as a distinct risk factor for developing peripheral neuropathy during chemotherapy.⁴ The word “functional” is important here: a person’s blood B12 level might look normal on a standard test, but the vitamin isn’t actually doing its job in cells. MMA is a more sensitive indicator of whether B12 is working properly, and elevated MMA predicted neuropathy risk better than B12 blood levels alone.

Once neuropathy sets in, the treatment options are limited and often unsatisfying. However, methylcobalamin (an active form of B12) has shown some promise in small trials. In one study, a combination treatment that included methylcobalamin improved neuropathy scores, numbness, and tingling compared to standard care in patients with non-small cell lung cancer who developed nerve damage from chemotherapy.⁵ Another comparative trial found that methylcobalamin and vitamin E were both more effective than glutamine or acetyl-L-carnitine at relieving sensory, motor, and pain symptoms of paclitaxel-induced neuropathy.⁶ These studies are small, and no major guidelines yet recommend routine methylcobalamin for neuropathy prevention, but the findings are enough for many oncologists to check B12 status before starting neurotoxic regimens.

The Uncomfortable Question About B12 Supplements and Breast Cancer

Not all the evidence around B12 and chemotherapy points in the same direction. One finding that caught the oncology community’s attention came from a large cooperative group trial (SWOG S0221) in women with breast cancer. Researchers tracked supplement use during chemotherapy and found that patients who took B12 supplements both before and during treatment had roughly double the risk of death and significantly poorer disease-free survival compared to those who did not.⁷ The association was striking, with an adjusted hazard ratio of about 2.0 for overall survival.

This is an observational finding within a trial, not a randomized test of B12 itself, so it doesn’t prove causation. Women who chose to take B12 may have differed from those who didn’t in ways the researchers couldn’t fully account for. However, a plausible biological story exists: if chemotherapy is trying to starve cancer cells of the DNA-building resources they need, flooding the system with extra B12 could theoretically blunt that effect. The one-carbon metabolism pathway that B12 feeds is precisely the pathway that antifolate drugs are trying to shut down.

A single-center study that looked specifically at luminal A and B breast cancer patients found no difference in disease-free or overall survival between those who received B12 and those who did not.⁸ Median disease-free survival was virtually identical in both groups. So the evidence is genuinely mixed, and the honest answer right now is that we don’t know whether supplemental B12 helps, hurts, or does nothing for most cancer types during treatment. The concern is real enough that oncologists generally advise against high-dose B12 supplements during chemotherapy unless there’s a documented deficiency or a specific protocol requirement like pemetrexed.

What Unusually High B12 Levels in Blood Actually Mean

Patients sometimes learn during cancer workups that their blood B12 levels are very high, and this can cause confusion. Elevated B12 in the blood doesn’t mean you’ve been taking too many supplements. In many cancer patients, high serum B12 is a marker of the disease itself, not a cause of it. Tumors, particularly liver-involved cancers and blood cancers, can release B12-binding proteins into the bloodstream that inflate the measured level.

A population-based cohort study from Denmark found that cancer patients with the highest B12 levels had markedly worse survival. One-year survival dropped from about 69% in those with moderately elevated B12 to roughly 36% in those with the highest levels. The association followed a dose-response pattern and held across multiple time windows after diagnosis.⁹ A separate study of metastatic cancer patients found that those with high serum B12 survived a median of about 1.8 months compared to about 5 months in the normal-B12 group, and high B12 remained an independent predictor of shorter survival even after accounting for other factors.¹⁰

Persistently elevated plasma B12, specifically levels above 1,000 ng/mL that remained high on repeat testing, has also been linked to an increased likelihood of being diagnosed with a solid tumor in the future, with one study reporting a hazard ratio near 6 compared to those with normal levels on both tests.¹¹ The takeaway for patients is that a high B12 blood level during cancer care is generally a reflection of how aggressive the disease is, not something caused by diet or supplements. Lowering B12 intake won’t change the prognosis.

Testing B12 Status in Cancer Patients Is Trickier Than It Sounds

Standard serum B12 tests are unreliable in people with cancer. Tumors can release B12-binding proteins that inflate the measured level, making a deficient patient look normal or even elevated. At the same time, cancer-related inflammation can lower binding proteins, creating the opposite distortion. Relying solely on a serum B12 number to make supplementation decisions during chemotherapy is a recipe for error.

Functional markers like methylmalonic acid and homocysteine give a better picture of whether B12 is actually working in cells. In cancer patients specifically, MMA outperforms serum B12 as a predictor of true B12 status. A study comparing the three markers in cancer patients found that MMA had an area under the curve of 0.98 for predicting combined B12 status, significantly higher than serum B12 at 0.83.¹² Oncology teams increasingly order MMA when neuropathy risk is high or when standard labs look inconsistent with the clinical picture.

After Gastrointestinal Surgery

Patients who have had portions of their stomach or intestines removed for cancer face a near-certain risk of B12 deficiency. The stomach produces intrinsic factor, a protein required for B12 absorption in the small intestine. After a total gastrectomy, absorption essentially stops, and even partial resections can slash it dramatically. Without replacement, deficiency develops over months to a few years as the body’s stored reserves deplete.

Scoping reviews of post-surgical recommendations for upper gastrointestinal cancer survivors consistently identify B12 and iron as the most important micronutrients to monitor and replace.¹³ For many years, the default replacement route was intramuscular injection, since oral B12 was assumed to be useless without intrinsic factor. But a dedicated study of gastric cancer patients after total gastrectomy found that high-dose oral B12 replacement was effective and safe, likely because a small percentage of the vitamin is absorbed passively, bypassing intrinsic factor.¹⁴ That has been good news for patients who dread regular injections or live far from medical facilities.

Prevalence of B12 deficiency across cancer populations varies widely, with estimates ranging from roughly 6% to nearly 50%, with the highest rates in elderly patients and those with gastrointestinal cancers. Chemotherapy itself contributes to the problem, since drugs that cause mucositis (inflammation and damage to the gut lining) can impair nutrient absorption even in patients who haven’t had surgery.

Nitrous Oxide and Surgery in B12-Deficient Patients

One danger that doesn’t get enough attention involves nitrous oxide, the anesthetic gas still used in some surgical settings. Nitrous oxide irreversibly oxidizes the cobalt atom at the center of B12, permanently inactivating the molecule.¹⁵ In someone with adequate B12 stores, this is usually inconsequential because the body has plenty of reserve. But in a patient who is already borderline or deficient, a single exposure to nitrous oxide during surgery can trigger rapid neurological deterioration known as subacute combined degeneration of the spinal cord.

A systematic review of reported cases confirmed that this pattern occurs even with a single exposure and that patients with unrecognized B12 deficiency are especially vulnerable.¹⁶ Cancer patients face heightened risk on two fronts: many arrive at surgery already depleted from poor nutrition, chemotherapy-related gut damage, or gastrointestinal tumors, and the surgery itself is often major. Researchers have also flagged that nitrous oxide may compound methotrexate neurotoxicity in pediatric leukemia patients by further reducing functional B12 levels. If you are a cancer patient heading into surgery, asking your anesthesia team about nitrous oxide use is reasonable, especially if you have any known risk factors for B12 deficiency.

Children with Cancer and B12

B12 deficiency is surprisingly common in children undergoing chemotherapy for acute lymphoblastic leukemia, the most frequent childhood cancer. A study of children about to begin induction chemotherapy found that about 37% were B12-deficient at baseline, and that deficiency was significantly associated with toxic deaths during the critical induction phase.¹⁷ These children often came from settings with pre-existing malnutrition, but the finding underscores how much baseline nutritional status influences tolerance to aggressive treatment.

Interestingly, among childhood leukemia survivors, B12 deficiency does not appear to predict who develops lasting neuropathy. A study comparing leukemia survivors with and without electrophysiologically confirmed neuropathy found no significant difference in B12 or folate levels between the two groups.¹⁸ That suggests the acute toxicity risk during treatment and the long-term nerve damage risk after treatment may involve different mechanisms, at least in children.

Nutritional Deficiency in Underserved Cancer Populations

B12 deficiency doesn’t affect all cancer patients equally. Women with cervical cancer in low-income regions, for instance, frequently arrive at diagnosis with pre-existing deficiencies in iron, folate, and B12, driven by inadequate dietary intake and sometimes chronic infections. Treatment side effects like nausea, vomiting, and mucositis then make it even harder to absorb and retain these nutrients, creating a vicious cycle where nutritional deficits worsen treatment tolerance, and treatment worsens nutritional status. In older adults, the problem compounds further because age-related changes in stomach acid production and gut absorption reduce B12 uptake even before cancer enters the picture.

B12 as a Drug Delivery Vehicle

One of the more creative chapters in B12 and cancer research involves exploiting the vitamin’s biology rather than just supplementing it. Cancer cells are greedy for B12 because they need it for rapid DNA replication. Many tumors overexpress the receptor (CD320) that pulls B12 into cells. Researchers have taken advantage of this by attaching B12 to drug-carrying nanoparticles. In gastric cancer cell models, B12-conjugated micelles were taken up more efficiently by cancer cells through this receptor pathway and were even able to reverse some forms of drug resistance.¹⁹ This is still preclinical work, nowhere near routine use, but it highlights the dual nature of B12 in oncology: the same property that makes oncologists cautious about high-dose supplementation during treatment might eventually be weaponized to deliver drugs more precisely to tumors.